326 related articles for article (PubMed ID: 27039126)
1. QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction.
Joseph J; Claggett BC; Anand IS; Fleg JL; Huynh T; Desai AS; Solomon SD; O'Meara E; Mckinlay S; Pitt B; Pfeffer MA; Lewis EF
JACC Heart Fail; 2016 Jun; 4(6):477-86. PubMed ID: 27039126
[TBL] [Abstract][Full Text] [Related]
2. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
[TBL] [Abstract][Full Text] [Related]
3. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
Pfeffer MA; Claggett B; Assmann SF; Boineau R; Anand IS; Clausell N; Desai AS; Diaz R; Fleg JL; Gordeev I; Heitner JF; Lewis EF; O'Meara E; Rouleau JL; Probstfield JL; Shaburishvili T; Shah SJ; Solomon SD; Sweitzer NK; McKinlay SM; Pitt B
Circulation; 2015 Jan; 131(1):34-42. PubMed ID: 25406305
[TBL] [Abstract][Full Text] [Related]
4. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Cikes M; Claggett B; Shah AM; Desai AS; Lewis EF; Shah SJ; Anand IS; O'Meara E; Rouleau JL; Sweitzer NK; Fang JC; Saksena S; Pitt B; Pfeffer MA; Solomon SD
JACC Heart Fail; 2018 Aug; 6(8):689-697. PubMed ID: 30007557
[TBL] [Abstract][Full Text] [Related]
5. Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial.
Merrill M; Sweitzer NK; Lindenfeld J; Kao DP
JACC Heart Fail; 2019 Mar; 7(3):228-238. PubMed ID: 30819379
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
Shah AM; Claggett B; Sweitzer NK; Shah SJ; Anand IS; Liu L; Pitt B; Pfeffer MA; Solomon SD
Circulation; 2015 Aug; 132(5):402-14. PubMed ID: 26130119
[TBL] [Abstract][Full Text] [Related]
7. Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial.
Lewis EF; Claggett B; Shah AM; Liu J; Shah SJ; Anand I; O'Meara E; Sweitzer NK; Rouleau JL; Fang JC; Desai AS; Retta TM; Solomon SD; Heitner JF; Stamos TD; Boineau R; Pitt B; Pfeffer MA
Circ Heart Fail; 2018 Mar; 11(3):e004457. PubMed ID: 29664406
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease.
Beldhuis IE; Myhre PL; Claggett B; Damman K; Fang JC; Lewis EF; O'Meara E; Pitt B; Shah SJ; Voors AA; Pfeffer MA; Solomon SD; Desai AS
JACC Heart Fail; 2019 Jan; 7(1):25-32. PubMed ID: 30606484
[TBL] [Abstract][Full Text] [Related]
9. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.
Lewis EF; Kim HY; Claggett B; Spertus J; Heitner JF; Assmann SF; Kenwood CT; Solomon SD; Desai AS; Fang JC; McKinlay SA; Pitt BA; Pfeffer MA;
Circ Heart Fail; 2016 Mar; 9(3):e001937. PubMed ID: 26962133
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
Shah AM; Claggett B; Sweitzer NK; Shah SJ; Deswal A; Anand IS; Fleg JL; Pitt B; Pfeffer MA; Solomon SD
Circ Heart Fail; 2015 Nov; 8(6):1052-8. PubMed ID: 26475142
[TBL] [Abstract][Full Text] [Related]
11. Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function.
Beldhuis IE; Myhre PL; Bristow M; Claggett B; Damman K; Fang JC; Fleg JL; McKinlay S; Lewis EF; O'Meara E; Pitt B; Shah SJ; Vardeny O; Voors AA; Pfeffer MA; Solomon SD; Desai AS
J Am Coll Cardiol; 2021 Mar; 77(9):1211-1221. PubMed ID: 33663739
[TBL] [Abstract][Full Text] [Related]
12. The frailty syndrome and outcomes in the TOPCAT trial.
Sanders NA; Supiano MA; Lewis EF; Liu J; Claggett B; Pfeffer MA; Desai AS; Sweitzer NK; Solomon SD; Fang JC
Eur J Heart Fail; 2018 Nov; 20(11):1570-1577. PubMed ID: 30225878
[TBL] [Abstract][Full Text] [Related]
13. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
Shen L; Jhund PS; Docherty KF; Petrie MC; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Swedberg K; Zile MR; McMurray JJV
JACC Heart Fail; 2019 May; 7(5):418-427. PubMed ID: 30981744
[TBL] [Abstract][Full Text] [Related]
14. Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure.
Vardeny O; Claggett B; Vaduganathan M; Beldhuis I; Rouleau J; O'Meara E; Anand IS; Shah SJ; Sweitzer NK; Fang JC; Desai AS; Lewis EF; Pitt B; Pfeffer MA; Solomon SD;
JACC Heart Fail; 2019 Dec; 7(12):1022-1028. PubMed ID: 31779923
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF).
Cannon JA; Collier TJ; Shen L; Swedberg K; Krum H; Van Veldhuisen DJ; Vincent J; Pocock SJ; Pitt B; Zannad F; McMurray JJ
Eur J Heart Fail; 2015 Jul; 17(7):707-16. PubMed ID: 26139584
[TBL] [Abstract][Full Text] [Related]
16. Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction.
Biering-Sørensen T; Shah SJ; Anand I; Sweitzer N; Claggett B; Liu L; Pitt B; Pfeffer MA; Solomon SD; Shah AM
Eur J Heart Fail; 2017 Aug; 19(8):1043-1052. PubMed ID: 28322009
[TBL] [Abstract][Full Text] [Related]
17. Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?
Mitter SS; Shah SJ
Curr Atheroscler Rep; 2015 Nov; 17(11):64. PubMed ID: 26408016
[TBL] [Abstract][Full Text] [Related]
18. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial.
Shah AM; Claggett B; Sweitzer NK; Shah SJ; Anand IS; O'Meara E; Desai AS; Heitner JF; Li G; Fang J; Rouleau J; Zile MR; Markov V; Ryabov V; Reis G; Assmann SF; McKinlay SM; Pitt B; Pfeffer MA; Solomon SD
Circ Heart Fail; 2014 Sep; 7(5):740-51. PubMed ID: 25122186
[TBL] [Abstract][Full Text] [Related]
19. Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension.
Tsujimoto T; Kajio H
J Am Heart Assoc; 2020 Dec; 9(23):e018827. PubMed ID: 33222584
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction: From the TOPCAT Study.
Vazir A; Claggett B; Pitt B; Anand I; Sweitzer N; Fang J; Fleg J; Rouleau J; Shah S; Pfeffer MA; Solomon SD
JACC Heart Fail; 2017 Nov; 5(11):782-791. PubMed ID: 29032132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
